Westfield Capital Management Co. LP Has $17.54 Million Holdings in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Westfield Capital Management Co. LP boosted its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 89.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,206,964 shares of the biotechnology company’s stock after acquiring an additional 569,604 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Momenta Pharmaceuticals were worth $17,537,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in Momenta Pharmaceuticals by 10.1% in the 1st quarter. BlackRock Inc. now owns 15,167,826 shares of the biotechnology company’s stock worth $220,387,000 after acquiring an additional 1,392,685 shares during the period. FMR LLC raised its position in shares of Momenta Pharmaceuticals by 25.7% in the 4th quarter. FMR LLC now owns 14,770,728 shares of the biotechnology company’s stock valued at $163,069,000 after purchasing an additional 3,023,513 shares in the last quarter. Primecap Management Co. CA raised its position in shares of Momenta Pharmaceuticals by 0.8% in the 1st quarter. Primecap Management Co. CA now owns 3,080,660 shares of the biotechnology company’s stock valued at $44,762,000 after purchasing an additional 23,965 shares in the last quarter. Perceptive Advisors LLC raised its position in shares of Momenta Pharmaceuticals by 11,435.8% in the 4th quarter. Perceptive Advisors LLC now owns 2,825,000 shares of the biotechnology company’s stock valued at $31,132,000 after purchasing an additional 2,800,511 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in shares of Momenta Pharmaceuticals by 31.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,598,642 shares of the biotechnology company’s stock valued at $28,689,000 after purchasing an additional 628,870 shares in the last quarter. Hedge funds and other institutional investors own 97.45% of the company’s stock.

Shares of MNTA opened at $11.98 on Friday. Momenta Pharmaceuticals, Inc. has a 52-week low of $9.55 and a 52-week high of $32.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.01). The firm had revenue of $4.11 million for the quarter, compared to analyst estimates of $10.12 million. Momenta Pharmaceuticals had a negative net margin of 231.49% and a negative return on equity of 43.98%. The business’s revenue was down 15.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.63) earnings per share. On average, equities analysts anticipate that Momenta Pharmaceuticals, Inc. will post -1.79 EPS for the current year.

MNTA has been the topic of a number of recent analyst reports. BidaskClub raised Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 20th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $16.00 target price on shares of Momenta Pharmaceuticals in a research report on Friday, February 22nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $29.00 target price on shares of Momenta Pharmaceuticals in a research report on Friday, February 22nd. Zacks Investment Research raised Momenta Pharmaceuticals from a “sell” rating to a “hold” rating and set a $16.00 target price on the stock in a research report on Monday, February 25th. Finally, BTIG Research initiated coverage on Momenta Pharmaceuticals in a research report on Monday, March 18th. They issued a “neutral” rating and a $14.15 target price on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $22.23.

In related news, Director Bruce Downey sold 13,000 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $14.51, for a total transaction of $188,630.00. Following the sale, the director now directly owns 41,234 shares of the company’s stock, valued at approximately $598,305.34. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Santiago Arroyo sold 8,119 shares of the company’s stock in a transaction that occurred on Tuesday, April 9th. The shares were sold at an average price of $15.00, for a total value of $121,785.00. Following the sale, the senior vice president now directly owns 39,803 shares in the company, valued at $597,045. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,800 shares of company stock worth $1,143,343. Corporate insiders own 3.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Westfield Capital Management Co. LP Has $17.54 Million Holdings in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2019/06/16/westfield-capital-management-co-lp-has-17-54-million-holdings-in-momenta-pharmaceuticals-inc-nasdaqmnta.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Further Reading: Green Investing

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.